Concurrent Exercise Training

The Impact of Morning Versus Evening Concurrent High-Intensity Interval Training and Resistance Training on Glycemic Control in in Men With Type 2 Diabetes Mellitus: A Randomized Controlled Trial

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07630025

Acronym

T2D

Enrollment

Registered

2026-06-05

Start date

2026-06-01

Completion date

2026-10-01

Last updated

2026-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Typ 2 Diabetes

Keywords

Diabetes, High Intensity Interval Trainin, resistance trsaining, glycemic control

Brief summary

The goal of this clinical trial is to investigate the influence of morning versus evening concurrent training consisting of high-intensity interval training and resistance training on glycemic control in men with type 2 diabetes mellitus. The main questions it aims to answer are: • Which time is best for concurrent exercise training in diabetic patients, morning or evening? Researchers will compare morning versus evening concurrent training consisting of HIIT and RT on glycemic control in men with type 2 diabetes mellitus. Participants will: * Perform concurrent training consisting of high-intensity interval training and resistance training for 12 weeks * Visit the clinic before and after the 12-week experimental period for checkups and tests

Interventions

BEHAVIORALExercise

Morning concurrent high-intensity interval training and resistance training

BEHAVIORALexercise

evening concurrent high-intensity interval training and resistance training between 16:00 and 19:00

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

MALE

Age

40 Years to 60 Years

Healthy volunteers

Inclusion criteria

* men aged 40-60 years with a diagnosis of T2D * HbA1c levels between 7.0% and 9.0% * treatment with oral hypoglycemic agents for at least 6 months * a BMI \<30 kg/m² * a physically inactive

Exclusion criteria

* current insulin therapy * a cardiovascular event within the previous 6 months * cardiovascular, respiratory or musculoskeletal conditions that could limit participation in exercise training * body weight instability

Design outcomes

Primary

Measure	Time frame	Description
glycemic control	baseline and at 12 weeks.	HbA1c

Secondary

Measure	Time frame	Description
lipid profile	baseline and at 12 weeks	total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides
cardiorespiratory fitness	at baseline and at 12 weeks	VO2peak

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 6, 2026